Aug 5 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.97.Q2 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES DATA.AMPHORA NDA RESUBMISSION REMAINS ON TRACK FOR Q4 2019.UNRESTRICTED CASH WAS $50.7 MILLION AT JUNE 30, 2019, AS COMPARED TO $0.2 MILLION AT MARCH 31, 2019.
Full Article
June 24 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES INC FILES PROSPECTUS RELATES TO RESALE OF UP TO 13.9 MILLION SHARES OF CO'S COMMON STOCK BY SELLING SECURITYHOLDERS - SEC FILING.
Full Article
May 7 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.67.Q1 EARNINGS PER SHARE ESTIMATE $-0.41 -- REFINITIV IBES DATA.
Full Article
March 1 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.58.Q4 EARNINGS PER SHARE ESTIMATE $-0.43 -- REFINITIV IBES DATA.ALSO EXPLORING AMPHORA'S POTENTIAL BEYOND CONTRACEPTION.UNRESTRICTED CASH WAS $1.3 MILLION AT DECEMBER 31, 2018, AS COMPARED TO $12.1 MILLION AT SEPTEMBER 30, 2018.
Full Article
Nov 7 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.71.Q3 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.EVOFEM BIOSCIENCES- EXPECTS QUARTERLY CASH BURN TO DECREASE TO APPROXIMATELY $7 TO 9 MILLION DURING Q4 OF 2018.
Full Article
March 16 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES INC FILES FOR SECONDARY OFFERING OF UP TO 17 MILLION SHARES - SEC FILING.
Full Article
Oct 17 (Reuters) - Neothetics Inc :Neothetics says if merger agreement with Evofem Biosciences terminated under specified circumstances, co to pay Evofem termination fee of up to $1.5 mln.
Full Article
Oct 17 (Reuters) - Neothetics Inc :Neothetics Inc and Evofem Biosciences, Inc. announce merger agreement to create Women’S health company.Neothetics Inc - privately-held Evofem Biosciences will merge with a wholly-owned subsidiary of Neothetics in an all-stock transaction.Neothetics - Invesco Asset Management entered securities purchase agreement to acquire additional $20 million of common stock in combined Co.Neothetics Inc - transactions have been approved by board of directors of both companies.Neothetics - Neothetics will be renamed Evofem Biosciences and will be under leadership of Evofem Biosciences' CEO Saundra Pelletier.Neothetics Inc - merger exchange ratio assumes $171.4 million in value of Co's common stock will be issued to Evofem Biosciences stockholders in merger.Neothetics - current Neothetics stockholders to own about 13% of combined company & current Evofem stockholders to own about 87% of combined company.Neothetics Inc - merger exchange ratio assumes $28.6 million in value of common stock being retained by Neothetics stockholders.Neothetics Inc - following merger, company will be led by Saundra Pelletier as chief executive officer.
Full Article
Earnings vs. 
Estimates